MURAL ONCOLOGY PLC(NASDAQ:MURA) stock Fundamental Analysis

Fundamental Rating

Overall MURA gets a fundamental rating of 2 out of 10. We evaluated MURA against 568 industry peers in the Biotechnology industry. MURA has a great financial health rating, but its profitability evaluates not so good. MURA has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

MURA had negative earnings in the past year.

In the past year MURA has reported a negative cash flow from operations.

1.2 Ratios

With a Return On Assets value of -75.87%, MURA is not doing good in the industry: 67.25% of the companies in the same industry are doing better.

The Return On Equity of MURA (-91.47%) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-75.87%
ROE	-91.47%
ROIC	N/A

ROA(3y)-235.67%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MURA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MURA has more shares outstanding than it did 1 year ago.

MURA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

MURA has an Altman-Z score of -2.15. This is a bad value and indicates that MURA is not financially healthy and even has some risk of bankruptcy.

MURA has a Altman-Z score (-2.15) which is in line with its industry peers.

There is no outstanding debt for MURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-2.15

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

MURA has a Current Ratio of 5.84. This indicates that MURA is financially healthy and has no problem in meeting its short term obligations.

MURA's Current ratio of 5.84 is fine compared to the rest of the industry. MURA outperforms 63.03% of its industry peers.

MURA has a Quick Ratio of 5.84. This indicates that MURA is financially healthy and has no problem in meeting its short term obligations.

MURA has a better Quick ratio (5.84) than 63.56% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.84
Quick Ratio	5.84

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MURA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.02%, which is quite impressive.

EPS 1Y (TTM)39.02%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%43.71%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 11.94% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y33.12%

EPS Next 2Y27.3%

EPS Next 3Y20.06%

EPS Next 5Y11.94%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MURA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MURA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

MURA's earnings are expected to grow with 20.06% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y27.3%

EPS Next 3Y20.06%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

MURA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MURAL ONCOLOGY PLC

NASDAQ:MURA (4/17/2025, 8:00:00 PM)

After market: 2.6418 -0.06 (-2.16%)

2.7

+0.28 (+11.57%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)03-11 2025-03-11/amc

Earnings (Next)N/A N/A

Inst Owners67.28%

Inst Owner ChangeN/A

Ins Owners1.12%

Ins Owner Change23.79%

Market Cap46.52M

Analysts78

Price Target6.12 (126.67%)

Short Float %2.11%

Short Ratio2.25

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)2.74%

Min EPS beat(2)-0.67%

Max EPS beat(2)6.14%

EPS beat(4)3

Avg EPS beat(4)10.42%

Min EPS beat(4)-0.67%

Max EPS beat(4)32.18%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-63.08%

PT rev (3m)-63.27%

EPS NQ rev (1m)8.55%

EPS NQ rev (3m)11.13%

EPS NY rev (1m)-6.42%

EPS NY rev (3m)-5.37%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.33
P/tB	0.33
EV/EBITDA	N/A

EPS(TTM)-7.58

EYN/A

EPS(NY)-5.07

Fwd EYN/A

FCF(TTM)-7.47

FCFYN/A

OCF(TTM)-7.46

OCFYN/A

SpS0

BVpS8.15

TBVpS8.15

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-75.87%
ROE	-91.47%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-235.67%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	2.62%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.84
Quick Ratio	5.84
Altman-Z	-2.15

F-Score3

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)167.92%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)39.02%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%43.71%

EPS Next Y33.12%

EPS Next 2Y27.3%

EPS Next 3Y20.06%

EPS Next 5Y11.94%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y29.54%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year52.38%

EBIT Next 3Y17.17%

EBIT Next 5Y8.57%

FCF growth 1Y34.93%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y33.82%

OCF growth 3YN/A

OCF growth 5YN/A

MURAL ONCOLOGY PLC (MURA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens